Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme
This cost-effectiveness analysis demonstrated that switching from PCV15 2 + 1 to PCV20 3 + 1 in the Dutch paediatric NIP would reduce both the clinical burden and projected costs of pneumococcal disease over 10 years.
Authors
- Johnna Perdrizet (ORCID: https://orcid.org/0000-0002-4260-7607)
- Esra Şükran Çakar (ORCID: https://orcid.org/0000-0002-3240-0557)
- Elizabeth Vinand
- Marion G. Peters (ORCID: https://orcid.org/0000-0002-1484-4752)
- An Ta (ORCID: https://orcid.org/0000-0003-0929-6365)
- Angela Waterval-Overbeek
- Aleksandar Ilic
Institutions
- Pfizer (United Kingdom) (GB)
- TransCanada (Canada) (CA)
- Pfizer (Netherlands) (NL)
- Pfizer (Canada) (CA)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1007/s40121-025-01109-2
- Citations
- 5
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 6.77
Funders
- Pfizer